Clinical review: Impact of statin substitution policies on patient outcomes

References

• European cardiovascular disease statistics. 2008. European Heart Network. Last update 14 Feb 2008. Available at:, , http://www.ehnheart.org/files/statistics%202008%20web-161229A.pdf ( accessed 29 Feb 2008).
   Google Scholar
• Graham I, Atar D, Borch-Johnsen K, Boysen G, Burell G, Cifkova R, et al. European guidelines on cardiovascular disease prevention in clinical practice: executive summary. Eur Heart J. 2007; 28: 2375–414
   PubMed Web of Science ®Google Scholar
• Wood, D. Clinical reality of coronary prevention in Europe: A comparison of EUROASPIRE I, II and III surveys. Time trends in cardiovascular disease prevention in clinical practice September 1994–March 2007. ESC Congress 2007 press releases. Last update 2 Sep 2007. Available at: http://www.escardio.org/vpo/press + area/2007-esc-congress-pr/wood-euroaspire.htm ( accessed 10 Oct 2007).
   Google Scholar
• Geller JC, Cassens S, Brosz M, Keil U, Bernarding J, Kropf S, et al. Achievement of guideline-defined treatment goals in primary care: the German Coronary Risk Management (CoRiMa) study. Eur Heart J. 2007; 28: 3051–8
   Google Scholar
• Baigent C, Keech A, Kearney PM, Blackwell L, Buck G, Pollicino C, et al. Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins. Lancet. 2005; 366: 1267–78
   PubMed Web of Science ®Google Scholar
• Muller-Nordhorn J, Binting S, Roll S, Willich SN. An update on regional variation in cardiovascular mortality within Europe. Eur Heart J. 2008; 29: 1316–26
   PubMed Web of Science ®Google Scholar
• Primatesta P, Poulter NR. Levels of dyslipidaemia and improvement in its management in England: results from the Health Survey for England 2003. Clin Endocrinol (Oxf). 2006; 64: 292–8
   PubMed Web of Science ®Google Scholar
• Keevil JG, Cullen MW, Gangnon R, McBride PE, Stein JH. Implications of cardiac risk and low-density lipoprotein cholesterol distributions in the United States for the diagnosis and treatment of dyslipidemia: data from National Health and Nutrition Examination Survey 1999 to 2002. Circulation. 2007; 115: 1363–70
   PubMed Web of Science ®Google Scholar
• Gaede P, Vedel P, Larsen N, Jensen G, Parving H, Pedersen O. Multifactorial intervention and cardiovascular disease in patients with type 2 diabetes. N Engl J Med. 2003; 348: 383–93
   PubMed Web of Science ®Google Scholar
• Gaede P, Pedersen O. Intensive integrated therapy of type 2 diabetes: implications for long-term prognosis. Diabetes. 2004; 53 Suppl 3: S39–47
   Google Scholar
• Laatikainen T, Critchley J, Vartiainen E, Salomaa V, Ketonen M, Capewell S. Explaining the decline in coronary heart disease mortality in Finland between 1982 and 1997. Am J Epidemiol. 2005; 162: 764–73
   PubMed Web of Science ®Google Scholar
• Steg PG, Goldberg RJ, Gore JM, Fox KA, Eagle KA, Flather MD, et al. Baseline characteristics, management practices, and in-hospital outcomes of patients hospitalized with acute coronary syndromes in the Global Registry of Acute Coronary Events (GRACE). Am J Cardiol. 2002; 90: 358–63
   PubMed Web of Science ®Google Scholar
• Goldberg RJ, Currie K, White K, Brieger D, Steg PG, Goodman SG, et al. Six-month outcomes in a multinational registry of patients hospitalized with an acute coronary syndrome (the Global Registry of Acute Coronary Events (GRACE)). Am J Cardiol. 2004; 93: 288–93
   PubMedGoogle Scholar
• Foley KA, Simpson RJ, Jr, Crouse JR 3rd, Weiss TW, Markson LE, Alexander CM. Effectiveness of statin titration on low-density lipoprotein cholesterol goal attainment in patients at high risk of atherogenic events. Am J Cardiol. 2003; 92: 79–81
   PubMed Web of Science ®Google Scholar
• Gislason GH, Rasmussen JN, Abildstrom SZ, Gadsboll N, Buch P, Friberg J, et al. Long-term compliance with beta-blockers, angiotensin-converting enzyme inhibitors, and statins after acute myocardial infarction. Eur Heart J. 2006; 27: 1153–8
   PubMed Web of Science ®Google Scholar
• Gajdos M, Krivosikova Z, Uhliar R. A critical gap between recommended and achieved LDL-cholesterol levels. Results of statin therapy in Slovakia. Bratisl Lek Listy. 2007; 108: 388–92
   Google Scholar
• Baessler A, Fischer M, Huf V, Mell S, Hengstenberg C, Mayer B, et al. Failure to achieve recommended LDL cholesterol levels by suboptimal statin therapy relates to elevated cardiac event rates. Int J Cardiol. 2005; 101: 293–8
   PubMed Web of Science ®Google Scholar
• Bassand JP, Hamm CW, Ardissino D, Boersma E, Budaj A, Fernandez-Aviles F, et al. Guidelines for the diagnosis and treatment of non-ST-segment elevation acute coronary syndromes. Eur Heart J. 2007; 28: 1598–660
   PubMed Web of Science ®Google Scholar
• Ryden L, Standl E, Bartnik M, Van den Berghe G, Betteridge J, de Boer MJ, et al. Guidelines on diabetes, pre-diabetes, and cardiovascular diseases: executive summary. The Task Force on Diabetes and Cardiovascular Diseases of the European Society of Cardiology (ESC) and of the European Association for the Study of Diabetes (EASD). Eur Heart J. 2007; 28: 88–136
   PubMed Web of Science ®Google Scholar
• Fox K, Garcia MA, Ardissino D, Buszman P, Camici PG, Crea F, et al. Guidelines on the management of stable angina pectoris: executive summary: the Task Force on the Management of Stable Angina Pectoris of the European Society of Cardiology. Eur Heart J. 2006; 27: 1341–81
   PubMed Web of Science ®Google Scholar
• De Backer G, Ambrosioni E, Borch-Johnsen K, Brotons C, Cifkova R, Dallongeville J, et al. European guidelines on cardiovascular disease prevention in clinical practice. Third Joint Task Force of European and Other Societies on Cardiovascular Disease Prevention in Clinical Practice. Eur Heart J. 2003; 24: 1601–10
   PubMed Web of Science ®Google Scholar
• Kearney PM, Blackwell L, Collins R, Keech A, Simes J, Peto R, et al. Efficacy of cholesterol-lowering therapy in 18,686 people with diabetes in 14 randomised trials of statins: a meta-analysis. Lancet. 2008; 371: 117–25
   PubMed Web of Science ®Google Scholar
• LaRosa JC, Grundy SM, Waters DD, Shear C, Barter P, Fruchart JC, et al. Intensive lipid lowering with atorvastatin in patients with stable coronary disease. N Engl J Med. 2005; 352: 1425–35
   PubMed Web of Science ®Google Scholar
• LaRosa JC, Grundy SM, Kastelein JJ, Kostis JB, Greten H. Safety and efficacy of atorvastatin-induced very low-density lipoprotein cholesterol levels in patients with coronary heart disease (a post hoc analysis of the Treating to New Targets (TNT) study). Am J Cardiol. 2007; 100: 747–52
   PubMed Web of Science ®Google Scholar
• Pedersen TR, Faergeman O, Kastelein JJ, Olsson AG, Tikkanen MJ, Holme I, et al. High-dose atorvastatin vs usual-dose simvastatin for secondary prevention after myocardial infarction: the IDEAL study: a randomized controlled trial. JAMA. 2005; 294: 2437–45
   PubMed Web of Science ®Google Scholar
• Cannon C, Braunwald E, McCabe C, Rader D, Rouleau J, Belder R, et al. Intensive versus moderate lipid lowering with statins after acute coronary syndromes. N Engl J Med. 2004; 350: 1495–504
   PubMed Web of Science ®Google Scholar
• de Lemos JA, Blazing MA, Wiviott SD, Lewis EF, Fox KA, White HD, et al. Early intensive vs a delayed conservative simvastatin strategy in patients with acute coronary syndromes: phase Z of the A to Z trial. JAMA. 2004; 292: 1307–16
   PubMed Web of Science ®Google Scholar
• Cannon CP, Steinberg BA, Murphy SA, Mega JL, Braunwald E. Meta-analysis of cardiovascular outcomes trials comparing intensive versus moderate statin therapy. J Am Coll Cardiol. 2006; 48: 438–45
   PubMed Web of Science ®Google Scholar
• Silva M, Matthews ML, Jarvis C, Nolan NM, Belliveau P, Malloy M, et al. Meta-analysis of drug-induced adverse events associated with intensive-dose statin therapy. Clin Ther. 2007; 29: 253–60
   PubMed Web of Science ®Google Scholar
• Sever P, Dahlof B, Poulter N, Wedel H, Beevers G, Caulfield M, et al. Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial—Lipid Lowering Arm (ASCOT-LLA): a multicentre randomised controlled trial. Lancet. 2003; 361: 1149–58
   PubMed Web of Science ®Google Scholar
• Ridker PM, Danielson E, Fonseca FA, Genest J, Gotto AM, Jr, Kastelein JJ, et al. Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. N Engl J Med. 2008; 359: 2195–207
   PubMed Web of Science ®Google Scholar
• Koren MJ, Hunninghake DB. Clinical outcomes in managed-care patients with coronary heart disease treated aggressively in lipid-lowering disease management clinics: the alliance study. J Am Coll Cardiol. 2004; 44: 1772–9
   PubMed Web of Science ®Google Scholar
• Dieleman JP, van Wyk JT, van Wijk MA, van Herpen G, Straus SM, Dunselman H, et al. Differences between statins on clinical endpoints: a population-based cohort study. Curr Med Res Opin. 2005; 21: 1461–8
   PubMed Web of Science ®Google Scholar
• Foody J, Joyce A, Rudolph A, Liu LZ, Benner J. Cardiovascular outcomes among patients newly initiating atorvastatin or simvastatin: a large database analysis of managed care plans in the US. Clin Ther. 2008; 30: 195–205
   PubMed Web of Science ®Google Scholar
• Ray KK, Cannon CP. Pathological changes in acute coronary syndromes: the role of statin therapy in the modulation of inflammation, endothelial function and coagulation. J Thromb Thrombolysis. 2004; 18: 89–101
   Google Scholar
• Hulten E, Jackson JL, Douglas K, George S, Villines TC. The effect of early, intensive statin therapy on acute coronary syndrome: a meta-analysis of randomized controlled trials. Arch Intern Med. 2006; 166: 1814–21
   PubMed Web of Science ®Google Scholar
• Schwartz G, Olsson A, Ezekowitz M, Ganz P, Oliver M, Waters D, et al. Effects of atorvastatin on early recurrent ischemic events in acute coronary syndromes: the MIRACL study: a randomized controlled trial. JAMA. 2001; 285: 1711–8
   PubMed Web of Science ®Google Scholar
• Thompson PL, Meredith I, Amerena J, Campbell TJ, Sloman JG, Harris PJ. Effect of pravastatin compared with placebo initiated within 24 hours of onset of acute myocardial infarction or unstable angina: the Pravastatin in Acute Coronary Treatment (PACT) trial. Am Heart J. 2004; 148: e2
   PubMed Web of Science ®Google Scholar
• Yun, KH, Jeong, MH, Oh, SK, Rhee, SJ, Park, EM, Lee, EM, , et al. The beneficial effect of high loading dose of rosuvastatin before percutaneous coronary intervention in patients with acute coronary syndrome. Int J Cardiol. 2008, Aug 13 (Epub ahead of print).
   Google Scholar
• Aronow HD, Topol EJ, Roe MT, Houghtaling PL, Wolski KE, Lincoff AM, et al. Effect of lipid-lowering therapy on early mortality after acute coronary syndromes: an observational study. Lancet. 2001; 357: 1063–8
   PubMed Web of Science ®Google Scholar
• Smith CS, Cannon CP, McCabe CH, Murphy SA, Bentley J, Braunwald E. Early initiation of lipid-lowering therapy for acute coronary syndromes improves compliance with guideline recommendations: observations from the Orbofiban in Patients with Unstable Coronary Syndromes (OPUS-TIMI 16) trial. Am Heart J. 2005; 149: 444–50
   Google Scholar
• Cannon, C, McCabe, C, Bentley, J, Braunwald, E. Early statin therapy is associated with markedly lower mortality in patients with acute coronary syndromes: Observations from OPUS-TIMI 16 [Abstract]. J Am Coll Cardiol. 2001;37 Suppl:A334.
   Google Scholar
• Stenestrand U, Wallentin L. Early statin treatment following acute myocardial infarction and 1-year survival. JAMA. 2001; 285: 430–6
   PubMed Web of Science ®Google Scholar
• Spencer FA, Allegrone J, Goldberg RJ, Gore JM, Fox KA, Granger CB, et al. Association of statin therapy with outcomes of acute coronary syndromes: the GRACE study. Ann Intern Med. 2004; 140: 857–66
   PubMed Web of Science ®Google Scholar
• Spencer FA, Goldberg RJ, Gore JM, Fox KA, Avezum A, Agnelli G, et al. Comparison of utilization of statin therapy at hospital discharge and six-month outcomes in patients with an acute coronary syndrome and serum low-density lipoprotein > or = 100 mg/dL versus <100 mg/dL. Am J Cardiol. 2007; 100: 913–8
   Google Scholar
• Fonarow GC, Wright RS, Spencer FA, Fredrick PD, Dong W, Every N, et al. Effect of statin use within the first 24 hours of admission for acute myocardial infarction on early morbidity and mortality. Am J Cardiol. 2005; 96: 611–6
   PubMed Web of Science ®Google Scholar
• Newman C, Tsai J, Szarek M, Luo D, Gibson E. Comparative safety of atorvastatin 80 mg versus 10 mg derived from analysis of 49 completed trials in 14,236 patients. Am J Cardiol. 2006; 97: 61–7
   PubMed Web of Science ®Google Scholar
• Kapur NK, Musunuru K. Clinical efficacy and safety of statins in managing cardiovascular risk. Vasc Health Risk Manag. 2008; 4: 341–53
   PubMedGoogle Scholar
• Garcia-Rodriguez LA, Gonzalez-Perez A, Stang MR, Wallander MA, Johansson S. The safety of rosuvastatin in comparison with other statins in over 25,000 statin users in the Saskatchewan Health Databases. Pharmacoepidemiol Drug Saf. 2008; 17: 953–61
   PubMedGoogle Scholar
• Garcia-Rodriguez LA, Masso-Gonzalez EL, Wallander MA, Johansson S. The safety of rosuvastatin in comparison with other statins in over 100,000 statin users in UK primary care. Pharmacoepidemiol Drug Saf. 2008; 17: 943–52
   PubMed Web of Science ®Google Scholar
• Alsheikh-Ali AA, Maddukuri PV, Han H, Karas RH. Effect of the magnitude of lipid lowering on risk of elevated liver enzymes, rhabdomyolysis, and cancer: insights from large randomized statin trials. J Am Coll Cardiol. 2007; 50: 409–18
   PubMed Web of Science ®Google Scholar
• Setoguchi S, Glynn RJ, Avorn J, Mogun H, Schneeweiss S. Statins and the risk of lung, breast, and colorectal cancer in the elderly. Circulation. 2007; 115: 27–33
   PubMed Web of Science ®Google Scholar
• Chan PS, Nallamothu BK, Gurm HS, Hayward RA, Vijan S. Incremental benefit and cost-effectiveness of high-dose statin therapy in high-risk patients with coronary artery disease. Circulation. 2007; 115: 2398–409
   PubMed Web of Science ®Google Scholar
• Koren M, Schwartz S, Drummond M. Cost-effectiveness of intensive therapy in patients with acute coronary syndrome [Abstract]. J Am Coll Cardiol. 2005; 45: 347A
   Google Scholar
• Taylor D, Pandya A, Thompson D, Chu P, Graff J, LaRosa J, et al. Cost-effectiveness of intensive lipid-lowering treatment in secondary cardiovascular prevention in Spain and Germany [Abstract]. Atheroscler Suppl. 2007; 8: 125
   Google Scholar
• Lindgren P, Graff J, Olsson AG, Pedersen TJ, Jonsson B. Cost-effectiveness of high-dose atorvastatin compared with regular dose simvastatin. Eur Heart J. 2007; 28: 1448–53
   PubMed Web of Science ®Google Scholar
• Straka RJ, Mamdani M, Damen J, Kuntze CE, Liu LZ, Botteman MF, et al. Economic impacts attributable to the early clinical benefit of atorvastatin therapy—a US managed care perspective. Curr Med Res Opin. 2007; 23: 1517–29
   PubMed Web of Science ®Google Scholar
• Yfantopoulos J, Papagiannopoulou V. Cost-effectiveness analysis of atorvastatin compared to simvastatin treatment in Greece. Arch Hel Med. 2007; 24: 463–70
   Google Scholar
• Ohsfeldt RL, Gandhi SK, Fox KM, McKenney JM. Statin cost-effectiveness comparisons using real-world effectiveness data: formulary implications. Value Health. 2008; 11: 1061–9
   PubMed Web of Science ®Google Scholar
• Harley CR, Gandhi SK, Heien H, McDonough K, Nelson SP. Lipid levels and low-density lipoprotein cholesterol goal attainment in diabetic patients: rosuvastatin compared with other statins in usual care. Expert Opin Pharmacother. 2008; 9: 669–76
   PubMed Web of Science ®Google Scholar
• Furberg CD, Herrington DM, Psaty BM. Are drugs within a class interchangeable?. Lancet. 1999; 354: 1202–4
   PubMed Web of Science ®Google Scholar
• Thiebaud P, Patel BV, Nichol MB, Berenbeim DM. The effect of switching on compliance and persistence: the case of statin treatment. Am J Manag Care. 2005; 11: 670–4
   PubMed Web of Science ®Google Scholar
• Hess G, Sanders KN, Hill J, Liu LZ. Therapeutic dose assessment of patient switching from atorvastatin to simvastatin. Am J Manag Care. 2007; 13 Suppl 3: S80–5
   Google Scholar
• Fox KM, Gandhi SK, Ohsfeldt RL, Davidson MH. Comparison of low-density lipoprotein cholesterol reduction after switching patients on other statins to rosuvastatin or simvastatin in a real-world clinical practice setting. Am J Manag Care. 2007; 13 Suppl 10: S270–5
   Google Scholar
• Phillips B, Aziz F, O'Regan C, Roberts C, Rudolph A, Morant S. Switching statins: the impact on patient outcomes. Br J Cardiol. 2007; 14: 280–5
   Google Scholar
• Thomas M, Mann J. Increased thrombotic vascular events after change of statin. Lancet. 1998; 352: 1830–1
   PubMed Web of Science ®Google Scholar
• Butler R, Wainwright J. Cholesterol lowering in patients with CHD and metabolic syndrome [Letter]. Lancet. 2007; 369: 27
   PubMed Web of Science ®Google Scholar
• Mantel-Teeuwisse AK, Goettsch WG, Klungel OH, de Boer A, Herings RM. Long term persistence with statin treatment in daily medical practice. Heart. 2004; 90: 1065–6
   PubMed Web of Science ®Google Scholar
• Benner JS, Pollack MF, Smith TW, Bullano MF, Willey VJ, Williams SA. Association between short-term effectiveness of statins and long-term adherence to lipid-lowering therapy. Am J Health Syst Pharm. 2005; 62: 1468–75
   PubMed Web of Science ®Google Scholar
• Petty D, Lloyd D. Can cheap generic statins achieve national cholesterol lowering targets?. J Health Serv Res Policy. 2008; 13: 99–102
   Google Scholar
• Usher-Smith J, Ramsbottom T, Pearmain H, Kirby M. Evaluation of the clinical outcomes of switching patients from atorvastatin to simvastatin and losartan to candesartan in a primary care setting: 2 years on. Int J Clin Pract. 2008; 62: 480–4
   PubMed Web of Science ®Google Scholar
• Usher-Smith JA, Ramsbottom T, Pearmain H, Kirby M. Evaluation of the cost savings and clinical outcomes of switching patients from atorvastatin to simvastatin and losartan to candesartan in a primary care setting. Int J Clin Pract. 2007; 61: 15–23
   PubMed Web of Science ®Google Scholar
• Miller AE, Hansen LB, Saseen JJ. Switching statin therapy using a pharmacist-managed therapeutic conversion program versus usual care conversion among indigent patients. Pharmacotherapy. 2008; 28: 553–61
   PubMed Web of Science ®Google Scholar